Cardio-pulmonary MRI for detection of treatment response after a single BPA treatment session in CTEPH patients
Chronic thromboembolic pulmonary hypertension (CTEPH) can be treated with balloon pulmonary angioplasty (BPA) in inoperable patients. Sensitive non-invasive imaging methods are missing to detect treatment response after a single BPA treatment session. Therefore, the aim of this study was to measure treatment response after a single BPA session using cardio-pulmonary MRI.
Materials and methods
Overall, 29 patients with CTEPH were examined with cardio-pulmonary MRI before and 62 days after their initial BPA session. Pulmonary blood flow (PBF), first-pass bolus kinetic parameters, and biventricular mass and function were determined. Multiple linear regression analysis was implemented to estimate the relationship of PBF change in the treated lobe with treatment change of full width at half maximum (FWHM), cardiac output (CO), ventricular mass index (VMI), pulmonary transit time (PTT) and PBF change in the non-treated lobes. Paired Wilcoxon rank sum test and Spearman rho correlation were used.
After BPA regional PBF increased in the treated lobe (p < 0.0001) as well as in non-treated lobes (p = 0.015). PBF treatment changes in the treated lobe were significantly larger compared with the non-treated lobes (p = 0.0049). Change in NT proBNP, MRI-derived mean pulmonary artery pressure (mPAP), PTT, FWHM, right ventricular (RV) ejection fraction, RV stroke volume, CO, VMI and PBF in the non-treated lobes correlated with PBF change in the treated lobe (p < 0.05). PBF changes in the treated lobe were independently predicted by PTT as well as PBF change in the non-treated lobes.
Cardio-pulmonary MRI detects and quantifies treatment response after a single BPA treatment session.
• Two months after BPA regional parenchymal pulmonary perfusion (PBF) increased in the total lung parenchyma (p = 0.005), the treated lobes (p < 0.0001) and non-treated lobes (p = 0.015).
• The PBF treatment changes in the treated lobe were significantly larger than in the non-treated lobes (p = 0.0049).
• Change in NT proBNP, MRI-derived mean pulmonary artery pressure, pulmonary transit time, full width at half maximum, right ventricular (RV) ejection fraction, RV stroke volume, cardiac output, ventricular mass index and PBF in the non-treated lobes correlated with PBF change in the treated lobe (p < 0.05).
KeywordsPulmonary hypertension Balloon angioplasty Perfusion Heart Magnetic resonance imaging
Six-minute walking distance
Balloon pulmonary angioplasty
Body surface area
Chronic thromboembolic pulmonary hypertension
Dynamic contrast enhanced
Full width at half maximum
Mean pulmonary artery pressure
N-terminal pro B-type natriuretic peptide
- NYHA FC
New York Heart Association functional classification
Pulmonary blood flow
Pulmonary transit time
Pulmonary vascular resistance
Right-sided heart catheterization
Time to peak
Time-resolved angiography with stochastic trajectories
Ventricular mass index
This study has received funding from the German Center for Lung Research (DZL).
Compliance with ethical standards
The scientific guarantor of this publication is Prof. Dr. Jens Vogel-Claussen.
Conflict of interest
The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.
Statistics and biometry
One of the authors has significant statistical expertise.
Written informed consent was obtained from all subjects (patients) in this study.
Institutional Review Board approval was obtained.
• performed at one institution
- 9.Ogo T, Fukuda T, Tsuji A et al (2017) Efficacy and safety of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension guided by cone-beam computed tomography and electrocardiogram-gated area detector computed tomography. Eur J Radiol 89:270–276. https://doi.org/10.1016/j.ejrad.2016.12.013 CrossRefPubMedGoogle Scholar
- 10.Mizoguchi H, Ogawa A, Munemasa M, Mikouchi H, Ito H, Matsubara H (2012) Refined balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv 5:748–755. https://doi.org/10.1161/CIRCINTERVENTIONS.112.971077 Google Scholar
- 11.Mayer E, Jenkins D, Lindner J et al (2011) Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: Results from an international prospective registry. J Thorac Cardiovasc Surg 141:702–710. https://doi.org/10.1016/j.jtcvs.2010.11.024 CrossRefPubMedGoogle Scholar
- 14.Inami T, Kataoka M, Shimura N et al (2014) Pressure-wire-guided percutaneous transluminal pulmonary angioplasty: a breakthrough in catheter-interventional therapy for chronic thromboembolic pulmonary hypertension. JACC Cardiovasc Interv 7:1297–1306. https://doi.org/10.1016/j.jcin.2014.06.010 CrossRefPubMedGoogle Scholar
- 15.Champion HC, Michelakis ED, Hassoun PM (2009) Comprehensive invasive and noninvasive approach to the right ventricle-pulmonary circulation unit: state of the art and clinical and research implications. Circulation 120:992–1007. https://doi.org/10.1161/CIRCULATIONAHA.106.674028 CrossRefPubMedGoogle Scholar
- 16.Roik M, Wretowski D, Łabyk A et al (2016) Refined balloon pulmonary angioplasty driven by combined assessment of intra-arterial anatomy and physiology - Multimodal approach to treated lesions in patients with non-operable distal chronic thromboembolic pulmonary hypertension - Technique, safety and efficacy of 50 consecutive angioplasties. Int J Cardiol 203:228–235. https://doi.org/10.1016/j.ijcard.2015.10.116 CrossRefPubMedGoogle Scholar
- 21.Simonneau G, D'Armini AM, Ghofrani HA et al (2016) Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial. Lancet Respir Med 4:372–380. https://doi.org/10.1016/S2213-2600(16)30022-4 CrossRefPubMedGoogle Scholar
- 23.American College of Cardiology Foundation Task Force on Expert Consensus Documents, Hundley WG, Bluemke DA et al (2010) ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. J Am Coll Cardiol 55:2614–2662Google Scholar
- 27.Schoenfeld C, Cebotari S, Hinrichs J et al (2016) MR imaging-derived regional pulmonary parenchymal perfusion and cardiac function for monitoring patients with chronic thromboembolic pulmonary hypertension before and after pulmonary endarterectomy. Radiology 279:925–934. https://doi.org/10.1148/radiol.2015150765 CrossRefPubMedGoogle Scholar
- 28.Galiè N, Humbert M, Vachiery JL et al (2016) 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 37:67–119. https://doi.org/10.1093/eurheartj/ehv317 CrossRefGoogle Scholar
- 33.Skrok J, Shehata ML, Mathai S et al (2012) Pulmonary arterial hypertension: MR imaging-derived first-pass bolus kinetic parameters are biomarkers for pulmonary hemodynamics, cardiac function, and ventricular remodeling. Radiology 263:678–687. https://doi.org/10.1148/radiol.12111001 CrossRefPubMedPubMedCentralGoogle Scholar
- 36.Vogel-Claussen J, Shehata ML, Lossnitzer D et al (2011) Increased right ventricular septomarginal trabeculation mass is a novel marker for pulmonary hypertension: comparison with ventricular mass index and right ventricular mass. Invest Radiol 46:567–575. https://doi.org/10.1097/RLI.0b013e31821b7041 CrossRefPubMedPubMedCentralGoogle Scholar
- 37.Swift AJ, Rajaram S, Hurdman J et al (2013) Noninvasive Estimation of PA Pressure, Flow, and Resistance With CMR Imaging: Derivation and Prospective Validation Study From the ASPIRE Registry. JACC Cardiovasc Imaging 6:1036–1047. https://doi.org/10.1016/j.jcmg.2013.01.013 CrossRefPubMedGoogle Scholar
- 38.Marra AM, Egenlauf B, Ehlken N et al (2015) Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Int J Cardiol 195:19–26. https://doi.org/10.1016/j.ijcard.2015.05.105 CrossRefPubMedGoogle Scholar
- 39.Yamasaki Y, Nagao M, Kamitani T et al (2016) Clinical impact of left ventricular eccentricity index using cardiac MRI in assessment of right ventricular hemodynamics and myocardial fibrosis in congenital heart disease. Eur Radiol 26:3617–3625. https://doi.org/10.1007/s00330-015-4199-9 CrossRefPubMedGoogle Scholar